Pharmaceutical company Collegium Pharmaceutical (NASDAQ: COLL) will be announcing earnings results this Thursday before market open. Here’s what investors should know.
Collegium Pharmaceutical beat analysts’ revenue expectations by 4.2% last quarter, reporting revenues of $188 million, up 29.4% year on year. It was a satisfactory quarter for the company, with an impressive beat of analysts’ revenue estimates but a significant miss of analysts’ EPS estimates.
Is Collegium Pharmaceutical a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, analysts are expecting Collegium Pharmaceutical’s revenue to grow 18.7% year on year to $189.1 million, improving from the 16.5% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.86 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Collegium Pharmaceutical has missed Wall Street’s revenue estimates twice over the last two years.
Looking at Collegium Pharmaceutical’s peers in the branded pharmaceuticals segment, some have already reported their Q3 results, giving us a hint as to what we can expect. Eli Lilly delivered year-on-year revenue growth of 53.9%, beating analysts’ expectations by 9.6%, and Supernus Pharmaceuticals reported revenues up 9.3%, topping estimates by 5.5%. Eli Lilly traded up 6% following the results.
Read our full analysis of Eli Lilly’s results here and Supernus Pharmaceuticals’s results here.
Investors in the branded pharmaceuticals segment have had steady hands going into earnings, with share prices flat over the last month. Collegium Pharmaceutical is up 5.7% during the same time and is heading into earnings with an average analyst price target of $44.60 (compared to the current share price of $35.76).
When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
